We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Special Survey on PD Patients With Renal Dysfunction

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT00613756
First Posted: February 13, 2008
Last Update Posted: November 13, 2013
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Information provided by:
Boehringer Ingelheim
  Purpose
The survey is conducted to collect safety and effectiveness information targeting patients who have both Parkinson's disease and renal dysfunction treated with Pramipexole in the daily clinical settings in Japan.

Condition
Parkinson Disease

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Post Marketing Surveillance of BI-Sifrol® (Pramipexole). Special Survey on Patients With Parkinson's Disease and Renal Dysfunction

Resource links provided by NLM:


Further study details as provided by Boehringer Ingelheim:

Primary Outcome Measures:
  • Incidence of adverse events [ Time Frame: up to 12 weeks ]
  • Incidence of adverse drug reactions (ADRs [ Time Frame: up to 12 weeks ]
  • Incidence of serious adverse events (SAEs) [ Time Frame: up to 12 weeks ]

Secondary Outcome Measures:
  • Modified Hoehn & Yahr rating scale [ Time Frame: change from baseline to week 12 ]
  • Unified Parkinson's Disease Rating Scale (UPDRS) part III total score [ Time Frame: change from baseline to week 12 ]
  • Physician's overall judgement by medical interview into 4 grades (5 categories) [ Time Frame: week 12 ]

Enrollment: 107
Study Start Date: February 2004
Primary Completion Date: September 2008 (Final data collection date for primary outcome measure)
  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   20 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients with idiopathic PD with renal dysfunction from Primary Care setting.
Criteria

Inclusion Criteria:

Patients with Parkinson's disease who have renal dysfunction with pretreatment creatinine clearance =<70mL/min or whose renal dysfunction was determined by the physician

Exclusion Criteria:

  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00613756


  Show 98 Study Locations
Sponsors and Collaborators
Boehringer Ingelheim
Investigators
Study Chair: Boehringer Ingelheim Boehringer Ingelheim
  More Information

Responsible Party: Boehringer Ingelheim, Study Chair, Boehringer Ingelheim
ClinicalTrials.gov Identifier: NCT00613756     History of Changes
Other Study ID Numbers: 248.548
First Submitted: January 31, 2008
First Posted: February 13, 2008
Last Update Posted: November 13, 2013
Last Verified: November 2013

Additional relevant MeSH terms:
Parkinson Disease
Renal Insufficiency
Parkinsonian Disorders
Basal Ganglia Diseases
Brain Diseases
Central Nervous System Diseases
Nervous System Diseases
Movement Disorders
Neurodegenerative Diseases
Kidney Diseases
Urologic Diseases